Dosing protocol · Weight Management
Pramlintide dosing & administration
Synthetic amylin analog for comprehensive postprandial glucose control with insulin therapy
Suggested dose
15 – 120 mcg
137 peptides · 10 goals
Goals
Cognitive
Cosmetic
Growth Hormone
Healing & Recovery
Hormone Support
Immune
Metabolic
Mitochondrial
Sexual Health
Sleep & Recovery
Dosing protocol · Weight Management
Synthetic amylin analog for comprehensive postprandial glucose control with insulin therapy
Suggested dose
15 – 120 mcg
Dosing
Subcutaneous
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
15 mcg per meal (type 1 diabetes)
FDA Symlin label starting dose for type 1 diabetes. Inject before each major meal (>=250 kcal or >=30 g carbohydrate); reduce mealtime insulin by 50% when starting.
30-60 mcg per meal (type 1 diabetes)
Type 1 maintenance target per FDA label: titrate 15 -> 30 -> 45 -> 60 mcg, stepping up each time no significant nausea occurs for 3+ days; settle at 30 or 60 mcg as tolerated.
60 mcg per meal, titrating to 120 mcg (type 2 diabetes)
FDA Symlin label for type 2 diabetes: start 60 mcg, advance to 120 mcg maintenance as tolerated. Separate injection from insulin; cut mealtime insulin 50% at start.
Timing
Best time to take
Administer Pramlintide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Pramlintide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Pramlintide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
Decrease if
Signs of right dose
Administration
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Pramlintide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Pramlintide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Pramlintide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Side effects
Commonly reported: Nausea, Reduced Appetite / Anorexia, Headache
Less common: Abdominal Pain and Vomiting, Injection Site Reactions
Serious side effects
Stop and seek help if
Pramlintide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
Published research
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Pramlintide is the first and only approved amylin analog, helping people with diabetes manage blood sugar and weight by suppressing glucagon, delaying stomach emptying, and boosting energy expenditure—working as a precision medicine approach for multi-hormone diabetes issues.
Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy
Post-hoc analysis of a 29-week randomised trial and a 6-month practice study of pramlintide added to insulin-pump therapy in type 1 diabetes: pramlintide reduced blood glucose excursions and raised the share of postprandial readings below 180 mg/dL, cut mealtime insulin by 23.8% (trial) and 27.5% (practice), and changed weight by −2.2 kg against +1.4 kg on placebo (trial) and −3.2 kg (practice). Short-lived, mostly mild-to-moderate nausea was the most common adverse event.
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes
In a 29-week study of type 1 diabetes patients on insulin, pramlintide cut postprandial blood sugar surges by nearly 2.7 times more than placebo and reduced body weight by 1.3 kilograms, without increasing dangerous low blood sugar episodes.
Pramlintide: A Review of Its Use in the Management of Insulin-Requiring Diabetes Mellitus
Research demonstrates pramlintide's effectiveness in improving glucose control across diverse patient populations with insulin-treated diabetes.
Amylin-mediated control of glycemia, energy balance, and cognition
Beyond blood sugar control, amylin (pramlintide) acts as a brain satiety signal that reduces hunger and weight, and emerging evidence suggests it may protect against Alzheimer's disease by reducing neurodegeneration in the brain.
SYMLIN (pramlintide acetate) injection - FDA Prescribing Information (DailyMed)
Head to head
The complete Pramlintide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.